Andrew Cook, MD, on the Potential Role of Gabapentin in Head and Neck Cancer

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to discuss the potential role of gabapentin in head and neck cancer despite garnering negative results in oropharynx cancer.

At the 2021 American Society for Radiation Oncology, CancerNetwork® spoke with Andrew Cook, MD, from Henry Ford Health System, about the potential use of gabapentin (Neurontin) in head and neck cancer following negative results in a population of patients with oropharynx cancer. Cook emphasized that although gabapentin did not appear particularly useful in the study’s population, it could have use in a post-surgical population of patients with head and neck cancer who are undergoing radiotherapy.


Negative findings are an important part of reporting findings in medicine. The role of gabapentin is still debated in its utilization for patients with head and neck cancer. The results from other studies have been mixed, [as to] whether it’s helpful or not. Our study was a little bit different than others. We used a very select group of patients with locally advanced oropharynx cancer [receiving] concurrent chemoradiotherapy. Given that we had negative findings regarding this patient population, we think that it’s unlikely that gabapentin is beneficial for this group of [patients. As] these negative results that can inform future studies, [we may how] resources should be directed in other ways.

Gabapentin may not be the most useful thing to study in the future, and there can be other strategies that can be looked at. I know right now in head and neck cancers, especially human papillomavirus–positive oropharynx cancer, treatment de-escalation or deintensification is a hot topic right now. That is something worthwhile that should be pursued; maybe different medications if people have ideas about that. It’s beneficial in terms of guiding future studies and future efforts from that standpoint. Also, again, it’s a very select group of patients, so I don’t think these results can be generalized to the entire head and neck cancer patient population. I think that gabapentin may still be beneficial for patients who’ve maybe undergone surgery and are getting radiation after or possibly different subsites. For this group, it seems to not [have worked].


Cook AE, Modh A, Ali H, et al. Randomized phase III, double-blind, placebo-controlled study of prophylactic gabapentin for the reduction of radiation therapy-induced pain during the treatment of oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2021; 111 (suppl 3): S61-S62. doi/10.1016/j.ijrobp.2021.07.156

Related Videos
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Shilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.
An expert from Stanford Medicine that the goal behind a study characterizing circulating tumor DNA and its predictive value is to eventually replace blood marrow exams with a blood draw for those with multiple myeloma.
Related Content